Insider & Institutional Ownership
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by company insiders. Comparatively, 28.0% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
Mangoceuticals Competitors | -742.83% | -44.77% | -34.17% |
Risk & Volatility
Mangoceuticals has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 3.73, meaning that their average share price is 273% more volatile than the S&P 500.
Valuation and Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
Mangoceuticals | $730,000.00 | -$9.21 million | -0.37 |
Mangoceuticals Competitors | $2.53 billion | $61.83 million | 11.08 |
Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Mangoceuticals competitors beat Mangoceuticals on 8 of the 9 factors compared.
Mangoceuticals Company Profile
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.